Metzger Michael A's Form 4 filing
Syndax Pharmaceuticals IncSNDX · filed Oct 4, 2022
- Accession no.
- 0001562180-22-007012
- Filed
- Oct 4, 2022
- Trade date
- Sep 30-Oct 4, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 3 derivative transactions. Open-market sales total $844.9K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Metzger Michael ACIK 0001507220 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 30, 2022 | Common Stock | MOption exerciseAcquired | +29,606 | $8.77 | +$259,644.62 | 47,265 | Direct | |
| Sep 30, 2022 | Common Stock | SSaleDisposed | −29,606 | $25.02F2 | −$740,742.12 | 17,659 | Direct | |
| Oct 3, 2022 | Common Stock | MOption exerciseAcquired | +2,883 | $8.77 | +$25,283.91 | 20,542 | Direct | |
| Oct 3, 2022 | Common Stock | SSaleDisposed | −2,883 | $25.01F3 | −$72,103.83 | 17,659 | Direct | |
| Oct 4, 2022 | Common Stock | MOption exerciseAcquired | +1,280 | $8.77 | +$11,225.6 | 18,939 | Direct | |
| Oct 4, 2022 | Common Stock | SSaleDisposed | −1,280 | $25.02F3 | −$32,025.6 | 17,659 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 30, 2022 | Common Stock | MOption exerciseDisposed | −29,606 | $0.00 | $0 | 0 | Direct | |
| Oct 3, 2022 | Common Stock | MOption exerciseDisposed | −2,883 | $0.00 | $0 | 0 | Direct | |
| Oct 4, 2022 | Common Stock | MOption exerciseDisposed | −1,280 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The sale prices ranged from $25.00 to $25.15.
Referenced by the price of 1 transaction in Table I.
- F3
The sale prices ranged from $25.00 to $25.03.
Referenced by the price of 2 transactions in Table I.